Table IV.

Correlations between mRNA levels and clinical characteristics.

Characteristic	Statistics	BRCA1	TYMS	STMN1	TOP2A	PDGFR	VEGFR2	KIT	HER2
Gender	r	0.179	0.287	0.052	0.245	−0.118	0.052	−0.137	−0.009
	P-value	0.083	0.005	0.618	0.017	0.256	0.618	0.187	0.928
Age (years)	r	0.036	0.008	−0.008	0.008	−0.171	−0.008	0.184	−0.080
	P-value	0.729	0.940	0.940	0.940	0.076	0.940	0.075	0.441
Stage	ρ	−0.056	0.012	−0.061	0.014	0.082	0.276	−0.216	0.140
	P-value	0.595	0.912	0.567	0.896	0.442	0.008	0.040	0.186
Primary tumor	ρ	−0.036	0.044	0.149	0.151	−0.102	−0.018	−0.161	−0.011
	P-value	0.738	0.681	0.164	0.159	0.340	0.864	0.132	0.921
Lymph nodes	ρ	−0.023	0.220	0.042	0.197	0.060	0.043	−0.111	0.075
	P-value	0.833	0.039	0.693	0.064	0.577	0.687	0.300	0.483
Distant metastasis	r	0.020	0.033	0.020	0.086	0.061	0.285	−0.139	0.217
	P-value	0.851	0.761	0.851	0.425	0.572	0.007	0.195	0.041
Histological type	r	−0.419	−0.293	−0.140	−0.247	0.107	0.107	−0.186	0.265
	P-value	0.000	0.004	0.180	0.017	0.305	0.305	0.073	0.010
Differentiation	ρ	−0.123	−0.264	−0.260	−0.098	−0.069	0.069	0.144	0.115
	P-value	0.272	0.016	0.018	0.383	0.540	0.540	0.197	0.304
Smoking history	r	0.275	0.254	0.054	0.298	−0.234	0.075	−0.122	−0.031
	P-value	0.009	0.015	0.609	0.004	0.026	0.482	0.249	0.774

The undetermined samples were not included in statistics. The cut-off point of the primary tumor was 3 cm. r, Pearson’s product-moment correlation coefficient; ρ, Spearman’s rank correlation coefficient; BRCA1, breast cancer 1; TYMS, thymidylate synthetase; STMN1, stathmin 1; TOP2A, topoisomerase II α; PDGFR, platelet-derived growth factor receptor; VEGFR2, vascular endothelial growth factor receptor 2; HER2, human epidermal growth factor receptor 2.